Skip to content
XPR
content.
Press releases
Video
Podcasts
Op-eds
Lists
Guest posts
Author:
BioInvent International
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer
August 7, 2026
BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models
July 28, 2026
BioInvent’s BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026
July 17, 2026
BioInvent’s TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)
June 11, 2026
BioInvent’s BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)
June 11, 2026